Niagen Bioscience, Inc.
NAGE Healthcare Biotechnology
Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024. In the quarter to June 2026, revenue fell 4.28%, EPS fell 80.0% and free cash flow grew 140.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow NAGE
Niagen Bioscience, Inc. (NAGE) EV/Sales
As of 16 October 2026, Niagen Bioscience, Inc. (NAGE) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.9× (October 2023) to 20.1× (November 2017); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.4× | (5.91%) |
| FY2024 | 3.6× | 269.76% |
| FY2023 | 1.0× | (28.99%) |
| FY2022 | 1.4× | (59.42%) |
| FY2021 | 3.4× | (27.69%) |
| FY2020 | 4.7× | (5.05%) |
| FY2019 | 4.9× | (7.11%) |
| FY2018 | 5.3× | (52.95%) |
| FY2017 | 11.3× | 89.77% |
| FY2016 | 6.0× | (18.61%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | (33.93%) |
| Mar 2026 | 2.2× | (35.20%) |
| Dec 2025 | 3.4× | (37.74%) |
| Sep 2025 | 5.5× | (41.30%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IFRX InflaRx N.V. compare | −1,061× |
| LYEL Lyell Immunopharma, Inc. compare | −550× |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | 0.7× |
| CGEN Compugen Ltd. compare | 0.8× |
| PRQR ProQR Therapeutics N.V. compare | 0.9× |
| NAGE Niagen Bioscience, Inc. | 1.0× |
| RNAC Cartesian Therapeutics, Inc. compare | 56.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)